[1]何法霖,王 薇,钟 堃,等.我国中孕期产前筛查不同检测系统室内质量控制现状与行业标准的比较[J].现代检验医学杂志,2018,33(01):154-157,160.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　HE Fa-lin,WANG Wei,ZHONG Kun,et al.Comparison of the Status of Internal Quality Control and Industry Standard of Different Platforms for Second Trimester Prenatal Screening in China[J].Journal of Modern Laboratory Medicine,2018,33(01):154-157,160.[doi:10.3969/j.issn.1671-7414.2018.01.001]
点击复制

我国中孕期产前筛查不同检测系统室内质量控制现状与行业标准的比较()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年01期
页码:
154-157,160
栏目:
质量控制·实验室管理
出版日期:
2018-02-05

文章信息/Info

Title:
Comparison of the Status of Internal Quality Control and Industry Standard of Different Platforms for Second Trimester Prenatal Screening in China
文章编号:
1671-7414(2018)01-154-05
作者:
何法霖; 王 薇; 钟 堃; 袁 帅; 杜雨轩; 王治国
北京医院 国家老年医学中心 卫生部临床检验中心/北京市临床检验工程技术研究中心,北京 100730
Author(s):
HE Fa-lin; WANG Wei; ZHONG Kun; YUAN Shuai; DU Yu-xuan; WANG Zhi-guo
National Center for Clinical Laboratories/Beijing Engineering Research Center for Clinical Laboratory/National Center for Gerontology,Beijing Hospital,Beijing 100730,China
关键词:
产前筛查;  唐氏综合征;  质量控制
分类号:
R446
DOI:
10.3969/j.issn.1671-7414.2018.01.001
文献标志码:
A
摘要:
目的 通过分析中孕期产前筛查不同检测系统室内质控现状与行业标准的差异,为提高产前筛查质量控制提供建议。方法 收集2016年全国468家产前筛查实验室9月份在控变异系数、累积在控变异系数,统计室内质控满足行业标准的比例,各检测系统组满足厂家要求及行业标准的比例。结果 AFP项目各检测系统满足厂家要求的实验室比例分布在34.9%～100%,满足行业标准要求的实验室比例分布在25.0%～78.0%; 总HCG项目满足厂家要求的实验室比例分布59.2%～81.6%,满足行业标准要求的比例分布在24.5%～30.6%; free β-hCG项目各检测系统满足厂家要求的实验室比例分布在38.9%～100%,满足行业标准要求的实验室比例分布在27.3%～63.0%; β-hCG项目各检测系统满足厂家要求的比例分布在14.3%～68.8%,满足行业标准要求的比例分布在14.3%～61.3%; UE3项目各检测系统满足厂家要求的比例分布在19.7%～100%,满足行业标准要求的比例分布在11.1%～54.8%。结论不论何种检测系统都存在室内质量控制不满足行业标准的实验室,实验室需要重视室内质量控制,保证检测系统满足产前筛查质量要求。
Abstract:
Abstract:Objective To analyzed the differences between the status of internal quality control and industry standard of different platforms in second trimester prenatal screening,so as to provide recommendations to improve prenatal screening quality control.Methods Collected the coefficient of variation in control and accumulatedcoefficient of variation in control of 468 prenatal screening laboratory in September 2016,and the proportion of the laboratory that meet the industry standard and analyze the proportion of different platforms that meet the manufacturersstandards and industry standards.Results For AFP,34.9%～100% of the laboratory meeted the manufacturers standards and 25%～78% meet theindustry standards; for total HCG,59.2%～81.6% of the laboratory meeted the manufacturers standards and 24.5%～30.6% meeted the industry standards,for freeβ-hCG,38.9%～100% of the laboratory meeted the manufacturers standards and27.3%～63.0% meeted the industry standards,for β-hCG,14.3%～68.8% of the laboratory meeted the manufacturers standards and 14.3%～61.3% meeted the industry standards.For uE3,19.7%～100% of the laboratory meeted the manufacturers standards and 11.1%～54.8% meeted the industry standards.ConclusionFailure to meet the industry standards happens to all platforms.Prenatal screening laboratories need to pay attention to internal quality control to ensure the performance of the platforms meet the quality requirements of prenatal screening.

参考文献/References:

[1] 吕时铭.选择适合我国现状的唐氏综合征产前筛查和诊断模式[J].诊断学理论与实践,2010,9(5):413-417.L(¨overu)SM.Pattern of prenatal screening and diagnosis for down syndrome suitable to corrent stute in China[J].Journal of Diagnostics Concepts & Practice,2010,9(5):413-417.
[2] WS322.1-2010.胎儿常见染色体异常与开发性神经管缺陷的产前筛查与诊断技术标准第1部分:中孕期母血清学产前筛查[S].北京:中国标准出版社,2010. Ministry of Health People's Republic of China.W S322.1-2010.Technical standards of prenatal screening and diagnosis for fetal common chromosomal abnormalities and open neural tube defects Part1.Maternal serum prenatal screening in second trimester[S].Beijing:Standards Press of China,2010.
[3] 边旭明,蒋宇林.重视唐氏综合征产前筛查的质量控制和评估[J].实用妇产科杂志,2014,30(2):81-83. Bian XM,Jiang YL.Quality control and evaluation of the prenatal screening of Down's syndrome[J].Journal of Practical Obstetric and Gynecology,2014,30(2):81-83.
[4] 姜 萍,张风琴,苍金荣.唐氏综合征和神经管畸形筛查实验的临床应用[J].现代检验医学杂志,2007,22(5):106-108. Jiang P,Zhang FQ,Cang JR.The clinical application of Down's syndrome and neural tube defects screening experiment[J].J Mod Lab Med,2007,22(5):106-108.
[5] 朱宝生,朱 姝.唐氏综合征血清学产前筛查室内质控的目标与方法[J].实用妇产科杂志,2014,30(2):89-93. Zhu BS,Zhu S.The goal and method of screening indoor quality control of the blood qingxue prenatal screening of down syndrome[J].Journal of Practical Obstetrics and Gynecology,2014,30(2):89-93.
[6] 刘珊玲,王 和.唐氏综合征产前筛查实验室质量控制[J].中华检验医学杂志,2011,34(7):665-668. Liu SL,Wang H.Laboratory quality control for Do-wn's syndrome[J].Clin J Lab Med,2011,34(7):665-668.
[7] 王治国.临床检验方法确认与性能验证[M].北京:人民卫生出版社,2014. Wang ZG.Clinical test method validation and performance verification[M].Beijing:People's Health Press,2014. 收稿日期:2017-04-26 修回日期:2017-10-11

相似文献/References:

[1]何法霖,王 薇,钟 堃,等.2015年全国中孕期母血清产前筛查相关指标的调查与分析[J].现代检验医学杂志,2017,32(01):154.[doi:10.3969/j.issn.1671-7414.2017.01.043]
　HE Fa-lin,WANG Wei,ZHONG Kun,et al.Survey and Analysis for Maternal Serum Marker of Prenatal Screening in Second Trimester in 2015[J].Journal of Modern Laboratory Medicine,2017,32(01):154.[doi:10.3969/j.issn.1671-7414.2017.01.043]
[2]张　燕,王　亿,缑灵山,等.孕妇外周血胎儿游离DNA 高通量测序在产前非整倍体核型遗传筛查中的应用[J].现代检验医学杂志,2020,35(02):6.[doi:10.3969/j.issn.1671-7414.2020.02.002]
　ZHANG Yan,WANG Yi,GOU Ling-shan,et al.Application of High-throughput Sequencing in Fetal Free DNA in MaternalPeripheral Blood in Prenatal Aneuploidy Karyotype Genetic Screening[J].Journal of Modern Laboratory Medicine,2020,35(01):6.[doi:10.3969/j.issn.1671-7414.2020.02.002]

备注/Memo

备注/Memo:
基金项目:北京市自然科学基金资助项目(7143182),北京医院课题资助(BJ-2015-025)。 作者简介:何法霖(1981-),女,硕士,副研究员,主要从事产前筛查和新生儿筛查质量控制工作,E-mail:flhe@nccl.org.cn。 通讯作者:王治国(1964-),男,教授,博士生导师,研究方向:实验室质量控制与管理,E-mail:zgwang@nccl.org.cn。
更新日期/Last Update: 2018-02-07